MAO-A/B-IN-3 

MAO-A/B-IN-3 (Compound 12) stands out as a key dual MAO-AChE inhibitor, displaying excellent multi-target efficacy against MAO-A, MAO-B, and AChE with IC₅₀ values of 67 nM, 29 nM, and 1370 nM respectively. MAO-A/B-IN-3 is adept at altering the A site (hydrophobic ring) and C site (semicarbazone chain) within ketone amine-based MTDLs to bolster the inhibitory potential against MAO-A/B while notably diminishing activity against AChE. MAO-A/B-IN-3 is poised for research applications in the field of neurodegenerative diseases^[1].

MAO-A/B-IN-3 (Compound 12) 在体外Caco2细胞穿透性实验中表现出中等的渗透性 (16.49 nm/s) ^[1]。
MAO-A/B-IN-3 对MDCK细胞显示出中等的穿透性 (103.16 nm/s) ^[1]。
MAO-A/B-IN-3 显示90.97%的血浆蛋白结合率，结合率大于90% 代表强结合率，表明它具有较长的半衰期和缓慢的排泄特性^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

MAO-A/B-IN-3 (Compound 12) (20 mg/kg；腹腔注射；60分钟) 增加了动物的不动期，因此被认为是中枢神经系统抑制剂^[1]。
MAO-A/B-IN-3 (30 mg/kg；腹腔注射；30分钟) 具有显著的抗焦虑活性，其中一些化合物显示出比参考药物地西泮更优越的活性^[1]。
MAO-A/B-IN-3 (30 mg/kg；腹腔注射；0.5小时和4小时) 在雄性白种小鼠中至少到4小时内不具有神经毒性^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

308.33

C₁₇H₁₆N₄O₂

315210-31-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kumar S, et al. Benzimidazole-derived carbohydrazones as dual monoamine oxidases and acetylcholinesterase inhibitors: design, synthesis, and evaluation[J]. Journal of Biomolecular Structure and Dynamics, 2023: 1-20.  [Content Brief]